Drug Trial Radar · NCT06164951
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Nov 10, 2023
Primary completion
Dec 18, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- QED Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QBGJ398-001).
Conditions
- Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/dayDrug
Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
Placebo Comparator 0.25 mg/kg/dayDrug
Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline (BL) in annualized height velocity (cm/year)Time frame: Week 52
Locations
27 sites in 10 countries. Site status is shown where the registry gives one.
QED Investigative Site
San Francisco, California
QED Investigative Site
Aurora, Colorado
QED Investigative Site
Baltimore, Maryland
QED Investigative Site
Columbia, Missouri
QED Investigative Site
Cincinnati, Ohio
QED Investigative Site
Nashville, Tennessee
QED Investigative Site
Madison, Wisconsin
QED Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina
QED Investigative Site
Parkville, Victoria, Australia
QED Investigative Site
Edmonton, Alberta, Canada
QED Investigative Site
London, Ontario, Canada
QED Investigative Site
Ottawa, Ontario, Canada
QED Investigative Site
Montreal, Quebec, Canada
QED Investigative Site
Bron, France
QED Investigative Site
Paris, France
QED Investigative Site
Toulouse, France
QED Investigative Site
Rome, Italy
QED Investigative Site
Bergen, Norway
QED Investigative Site
Oslo, Norway
QED Investigative Site
Singapore, Singapore
QED Investigative Site
Málaga, Spain
QED Investigative Site
Vitoria-Gasteiz, Spain
QED Investigative Site
Bristol, United Kingdom
QED Investigative Site
Glasgow, United Kingdom
QED Investigative Site
London, United Kingdom
QED Investigative Site
Manchester, United Kingdom
QED Investigative Site
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.